— Aurinia Pharmaceuticals (NASDAQ: AUPH) reported a fourth-quarter 2019 loss of $0.78 per share versus a loss of $0.14 per share expected.
— Revenue remained flat at $29,000 versus $40,000 expected. The top line was hurt by nil contract revenue.
— The bottom line was hurt by an increase in the estimated fair value of derivative warrant liabilities.
— Research and development expenses increased by 23% due to costs related to NDA submission preparation costs, higher personnel costs, higher costs incurred for the Aurora 2 extension trial, and the Audrey DES phase 2/3 study.
— During the second half of 2020, the company anticipates reporting interim data from the exploratory Phase 2 FSGS study and results from the Phase 2/3 Audrey DES trial evaluating 3 concentrations of VOS compared to the vehicle alone.
— The company believes it has sufficient financial resources to fund its current plans. This includes ongoing R&D programs, completing the NDA submission, manufacturing and packaging commercial drug supply required for launch, and fund its supporting corporate and working capital needs through 2021.
Listen to on-demand earnings calls and hear how management responds to analysts’ questions
Most Popular
Key highlights from Adobe (ADBE) Q2 2021 earnings results
Adobe Systems Incorporated (NASDAQ: ADBE) reported second quarter 2021 earnings results today. Total revenue grew 23% year-over-year to $3.84 billion. GAAP net income was $1.11 billion, or $2.32 per share,
Three factors that bode well for Delta Air Lines (DAL) going forward
Shares of Delta Air Lines Inc. (NYSE: DAL) have gained 45% over the past 12 months and 11% since the beginning of this year. After a particularly distressful period, like
KR Earnings: All you need to know about Kroger Q1 2021 earnings results
The Kroger Co. (NYSE: KR) reported first-quarter 2021 earnings results today. Total company sales were $41.3 billion compared to $41.5 billion in the same period last year. Excluding fuel, sales
